What is Expression Systems?
Expression Systems, LLC operates at the intersection of advanced molecular biology and industrial-scale biomanufacturing. The company specializes in the development and distribution of premium insect cell culture media, baculovirus expression systems, and essential biological buffers. Their flagship product, ESF AdvanCD, serves as a cornerstone for researchers aiming to optimize viral stock consistency and maximize cell growth yields. By providing both high-quality reagents and specialized contract services, such as baculovirus titering, the company acts as a foundational partner for organizations navigating the complexities of protein expression and therapeutic development. Their market position is defined by a commitment to technical precision, enabling clients to accelerate their R&D pipelines through reliable, standardized biological tools.
How much funding has Expression Systems raised?
Expression Systems has raised a total of $599K across 2 funding rounds:
Debt
$150K
Debt
$449K
Debt (2020): $150K with participation from PPP
Debt (2021): $449K led by PPP
Key Investors in Expression Systems
PPP
Public-Private Partnership
What's next for Expression Systems?
With the recent influx of capital, Expression Systems is well-positioned to transition into a more aggressive phase of enterprise-level expansion. The strategic focus will likely center on enhancing manufacturing throughput and broadening the distribution network for their proprietary media formulations. As the pharmaceutical industry continues to prioritize efficiency in viral vector production and recombinant protein synthesis, Expression Systems is poised to capture additional market share by scaling its service offerings. Future initiatives may include the integration of automated quality control protocols and the expansion of their contract research organization (CRO) capabilities to better serve global biopharma partners. This capital deployment strategy ensures the company remains at the forefront of the insect cell expression market, providing the necessary infrastructure for the next generation of biotherapeutic breakthroughs.
See full Expression Systems company page
